****COULD BE A GREAT MOVE IN THE DAYS TO SOME, AFTER VERY POSITIVE DATA FOR THEIR GEN-009 CANCER VACCINE******
Joseph Pantginis also upgraded the stock to $42 today, he states,
“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $42 from $5.75. The factors impacting our target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count subsequent to the 8 reverse split.”
COMPANY PROFILE
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.
Joseph Pantginis also upgraded the stock to $42 today, he states,
“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $42 from $5.75. The factors impacting our target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count subsequent to the 8 reverse split.”
COMPANY PROFILE
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.